Hoth Therapeutics, Inc.
1.3600-0.04 (-2.86%)
Oct 30, 4:00:02 PM EDT · NasdaqCM · HOTH · USD
Key Stats
Market Cap
18.03MP/E (TTM)
-Basic EPS (TTM)
-1.04Dividend Yield
0%Recent Filings
8-K
Hoth pipeline update filed
Hoth Therapeutics filed presentation materials on October 17, 2025, outlining its pipeline of clinical-stage biopharma assets targeting unmet needs in oncology, dermatology, neurology, and inflammatory diseases. Key highlights include HT-001, a topical gel in Phase 2a trials for EGFR inhibitor-induced skin toxicity, with positive interim data showing reduced inflammation and no approved competitors; HT-KIT advances toward IND submission in 2026 for mast cell cancers. The company reports 15.4 million shares outstanding and cash sufficient for ongoing programs. Investors should note forward-looking statements carry risks from clinical uncertainties.
8-K
Expands crypto treasury reserves
Hoth Therapeutics expanded its treasury reserve strategy on September 10, 2025, gaining board approval to buy up to $1 million in Bitcoin, Ethereum, or Solana, capped at 20% of cash on hand. This move diversifies holdings amid volatile crypto markets, yet exposes the biotech to sharp price swings and no dividend yields. Risks loom large. Untested strategy.
8-K
CEO contract renewed, patent filed
Hoth Therapeutics locked in CEO Robb Knie with a new employment agreement effective August 22, 2025, bumping his base salary to $550,000 and capping annual bonuses at the same amount, while adding a tiered transaction bonus up to 5.5% of equity value for deals like licensing or change of control. The board also granted him 800,000 fully vesting shares on August 27. Separately, the company filed a PCT patent application for HT-001 on August 20, bolstering its cancer treatment pipeline. This setup incentivizes Knie amid IP advances, yet ties payouts to performance hurdles.
10-Q
Q2 FY2025 results
Hoth Therapeutics posted a Q2 net loss of $2.2 million, up 29% year-over-year from $1.7 million, driven by research and development expenses that climbed to $1.0 million from $0.6 million, fueled by $0.7 million in HT-001 manufacturing and clinical work plus $0.3 million for HT-KIT preclinical efforts. The six-month net loss widened to $5.7 million, or $0.44 per share on 13.0 million diluted shares, versus $3.9 million, or $0.68 per share on 5.6 million shares last year, reflecting a $1.3 million patent acquisition expense in January. Cash swelled to $9.0 million, bolstered by $5.6 million from warrant exercises and $1.5 million from ATM sales, yielding $5.2 million in operating cash burn. No revenue yet, but liquidity covers operations for 12 months. Regulatory hurdles could delay approvals.
8-K
Hoth shareholders approve board, auditors
Hoth Therapeutics held its 2025 annual shareholder meeting on August 5, re-electing all five board directors—Robb Knie, David Sarnoff, Wayne Linsley, Jeff Pavell, and Chris Camarra—with strong support amid 4 million broker non-votes. Shareholders ratified Withum as auditors for 2025 and approved expanding the 2022 equity plan's share reserve to 3,091,317 from 1,091,317, despite a closer 912,522 for versus 538,671 against. They also backed annual advisory votes on executive pay and the 2024 compensation package. This bolsters governance continuity while enhancing equity incentives for talent retention.
ACRS
Aclaris Therapeutics, Inc.
2.34-0.05
EDSA
Edesa Biotech, Inc.
2.07-0.09
HCWB
HCW Biologics Inc.
3.85-0.04
HRTX
Heron Therapeutics, Inc.
1.17-0.02
KLTO
Klotho Neurosciences, Inc.
0.52-0.01
KROS
Keros Therapeutics, Inc.
15.04-0.14
ORKA
Oruka Therapeutics, Inc.
27.61+0.17
THAR
Tharimmune, Inc.
3.00+0.07
VNDA
Vanda Pharmaceuticals Inc.
5.41-0.17
XBIT
XBiotech Inc.
2.37+0.00